Safety and efficacy of PeaNoc XL tablets on arthritis index (WOMAC)
physical stiffness, pain
INFLAMMATION, ADVERSE DRUG REACTIONS
WOMAC questionnaire has three main areas such as pain score, joint stiffness, and physical stiffness. The addition of PeaNoc XL as an adjunct therapy demonstrated significant reductions in pain (P<0.001), joint stiffness (P<0.01), and physical stiffness (P<0.001) compared to baseline among patients with joint pain and inflammation. In contrast, standard therapy did not exhibit statistically significant differences in these parameters in the same patient population.
Following a 12-week treatment with PeaNoc XL therapy, all hematological and biochemical safety parameters remained within normal ranges. No severe adverse side effects were reported during the study period, and none of the patients withdrew their consent due to adverse drug reactions.